# CJC-1295 References: The Cited Research Record

> CJC-1295 references: the full citation list behind the digest — Teichman 2006, Ionescu/Frohman 2006, Jette 2005, Alba 2006, and the rest, with DOIs and PubMed links.

Every quantitative claim on this site resolves to one of these sources — the full flight-recorder citation register, with DOIs, PMIDs, and trial identifiers.

## The CJC-1295 references behind this digest

The CJC-1295 references below are the complete source set for this digest. The core human pharmacokinetics rest on Teichman 2006 and Ionescu/Frohman 2006 [1][3]; the molecular and animal foundation on Jette 2005 and Alba 2006 [2][4]; the regulatory and anti-doping context on the 2024 FDA PCAC review and Henninge 2010 [1][6]; and the class-level framing on the 2025 Nature Reviews Endocrinology review [13]. Each numbered entry corresponds to the inline markers used across [the human and animal research](/research) and the other pages.

The register is deliberately mixed by evidence type. Entries 1 and 3 are the foundational human pharmacokinetic studies — the measured telemetry the whole site is built around. Entries 2, 4, and 5 are the animal and mechanistic work that explains how the long-acting design produces those kinetics. Entry 6 is the analytical-chemistry identification of CJC-1295 in a seized preparation, and entry 7 is the discontinued ConjuChem Phase 2 registry record. Entries 12, 13, 14, and 16 supply the GH-physiology and class-level context — fluid retention, the GHRH-analog landscape, adult GH-deficiency guidance, and the unapproved-peptide safety review. Where a source disagrees with another on a chemical identifier, this digest flags the uncertainty in the body rather than resolving it silently.

## References

[1] Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. https://pubmed.ncbi.nlm.nih.gov/16352683/
[2] Jette L, Leger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. https://pubmed.ncbi.nlm.nih.gov/15817669/
[3] Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. https://pubmed.ncbi.nlm.nih.gov/17018654/
[4] Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. https://pubmed.ncbi.nlm.nih.gov/16822960/
[5] Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471-477. https://pubmed.ncbi.nlm.nih.gov/19386527/
[6] Henninge J, Pepaj M, Hullstein I, Hemmersbach P. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Test Anal. 2010;2(11-12):647-650. https://doi.org/10.1002/dta.233
[7] ConjuChem Inc. A study to evaluate CJC-1295 in HIV patients with visceral obesity. ClinicalTrials.gov; 2006. NCT00267527. https://clinicaltrials.gov/study/NCT00267527
[8] Growth hormone secretagogue treatment in hypogonadal men raises serum insulin-like growth factor-1 levels. Am J Mens Health. 2017. https://pubmed.ncbi.nlm.nih.gov/28830317/
[9] Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity. J Clin Endocrinol Metab. 2011. https://pubmed.ncbi.nlm.nih.gov/20943777/
[11] Modified GRF (1-29) — chemical and pharmacological description. Encyclopedic reference; 2024. https://en.wikipedia.org/wiki/Modified_GRF_(1-29)
[12] GH increases extracellular volume by stimulating sodium reabsorption in the distal nephron. J Clin Endocrinol Metab. 2002. https://pubmed.ncbi.nlm.nih.gov/11932310/
[13] Granata R, Leone S, Zhang X, Gesmundo I, et al. Growth hormone-releasing hormone and its analogues in health and disease. Nat Rev Endocrinol. 2025;21(3):180-195. https://pubmed.ncbi.nlm.nih.gov/39537825/
[14] A 2024 update on growth hormone deficiency syndrome in adults: from guidelines to clinical practice. J Clin Med. 2024;13(20):6079. https://pubmed.ncbi.nlm.nih.gov/39458028/
[15] Growth hormone and growth hormone secretagogue effects on nitrogen balance and urea kinetics. Growth Horm IGF Res. 2009. https://pubmed.ncbi.nlm.nih.gov/19231263/
[16] Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal conditions. Sports Med. 2026. https://pubmed.ncbi.nlm.nih.gov/41966639/

---

A flight-log read of the CJC-1295 record — measured telemetry where the studies exist, flagged gaps where they stop, no clinic behind the console and nothing here dispensed or sold.